This study was EPIC!
Recent groundbreaking research into canine heart disease is changing the way we treat one of the most common heart conditions.
It is estimated that one dog in ten may suffer from some type of heart disease and there it’s a particular type of heart disease called mitral valve disease that can lead to congestive heart failure, reduced quality of life and an overall shortened lifespan.
The EPIC (Evaluation of Pimobendan In dogs with Cardiomegaly) Study was the largest veterinary cardiology study in history. This groundbreaking study set out to answer a key question: Can a particular drug (pimobendan) delay the onset of congestive heart failure (CHF) in dogs with mitral valve disease?
The study, which began in 2010 and ran through to 2015, included investigators at 36 study centres in 11 nations across 4 continents. Investigators were held to rigorous scientific standards, and an independent team compiled and reported the findings.